Amneal Pharmaceuticals, Inc. P/E Ratio 2016–2025
Amneal Pharmaceuticals, Inc. reported 57.27 of price-to-earnings ratio for fiscal 2025. That was 16.3% lower than fiscal 2021. Compared with fiscal 2020, the change was +664.5%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 57.27 | — |
| FY 2024 | — | — |
| FY 2023 | — | — |
| FY 2022 | — | — |
| FY 2021 | 68.43 | +813.4% |
| FY 2020 | 7.49 | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
Source: Amneal Pharmaceuticals, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open AMRX 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Amneal Pharmaceuticals, Inc. reported 57.27 of price-to-earnings ratio for fiscal 2025. That was 16.3% lower than fiscal 2021. Compared with fiscal 2020, the change was +664.5%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Amneal Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeAmneal Pharmaceuticals, Inc. — frequently asked questions
What is Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio?
Amneal Pharmaceuticals, Inc. (AMRX) reported price-to-earnings ratio of 57.27 for fiscal year 2025, per its SEC filings.
How has Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2016 and 2025, AMRX's price-to-earnings ratio grew at roughly 25.4% per year (compound annual rate), from 7.49 to 57.27.
Where does this data come from?
Figures are computed from Amneal Pharmaceuticals, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More AMRX financial history
Full AMRX fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →